Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients

Journal of Clinical Oncology

Volumn 22, Issue 7, 2004, Pages 1222-1227

  Gassas, Adam ^a   Grant, Ronald ^a   Richardson, Susan ^a   Dupuis, L Lee ^a   Doyle, John ^a   Allen, Upton ^a   Abla, Oussama ^a   Sung, Lillian ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; ANTIINFECTIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIUM ISOLATION; CHILD; DRUG MEGADOSE; HOSPITAL PATIENT; HUMAN; HYPOTENSION; INFANT; INOTROPISM; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SEPTIC SHOCK; STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; NEOPLASM; PATHOLOGY; PREDICTION AND FORECASTING; PRESCHOOL CHILD; STREPTOCOCCUS INFECTION;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTEREMIA; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; TRANSPLANTATION, HOMOLOGOUS; VIRIDANS STREPTOCOCCI;

EID: 2142648657     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.09.108     Document Type: Article

References (32)

1. Pizzo PA, Ladisch S. Witebsky FG: Alpha-hemolytic streptococci: Clinical significance in the cancer patient. Med Pediatr Oncol 4:367-370, 1978
2. Hoecker JL, Pickering LK, Groschel D, et al: Streptococcus salivarius sepsis in children with malignancies. J Pediatr 92:337-338, 1978
3. Bochud PY, Eggiman P, Calandra T, et al: Bacteremia due to viridans streptococcus in neutropenic patients with cancer: Clinical spectrum and risk factors. Clin Infect Dis 18:25-31, 1994
4. Henslee J, Bostrom B, Weisdorf D, et al: Streptococcal sepsis in bone marrow transplant patients. Lancet 1:393, 1984
5. Villablanca JG. Steiner M, Kersey J, et al: The clinical spectrum of infections with viridans streptococci in bone marrow transplant patients. Bone Marrow Transplant 5:387-393, 1990
6. Martino R, Manteiga R, Sanchez I, et al: Viridans Streptococcal shock syndrome during bone marrow transplantation. Acta Haematol 94:69-73, 1995
7. Bilgrami S, Feingold JM, Dorsky D, et al: Streptococcus viridans bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 21:591-595, 1998
8. Hann I, Viscoli C. Paesmans M, et al: A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies-International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol 99:580-588, 1997
9. Martino R, Subira M, Manteiga R, et al: Viridans Streptococcal bacteremia and viridans Streptococcal shock syndrome in neutropenic patients: Comparison between children and adults receiving chemotherapy or undergoing bone marrow transplantation. Clin Infect Dis 20:476-477, 1995
10. Bochud PY, Calandra T, Francioli P: Bacteremia due to viridans streptococci in neutropenic patients: A review. Am J Med 97:256-264, 1994
11. Shenep JL: Viridans-group Streptococcal infections in immunocompromised hosts. Int J Antimicrob Agents 14:129-135, 2000
12. Rossetti F, Cesaro S, Putti MC, et al: High-dose cytosine arabinoside and viridans streptococcus sepsis in children with leukemia. Pediatr Hematol Oncol 12:387-392, 1995
13. Engelhard D, Elishoov H, Or R, et al: Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: A 5-year prospective study. Bone Marrow Transplant 16:565-570, 1995
14. Persson L, Vikerfors T, Sjoberg L, et al: Increased incidence of bacteraemia due to viridans streptococci in an unseiected population of patients with acute myeloid leukaemia. Scand J Infect Dis 32:615-621, 2000
15. Kern W, Kurrle E, Schmeiser T: Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy: A review of 55 cases. Infection 18:138-145, 1990
16. Elting LS, Bodey GP, Keefe BH: Septicemia and shock syndrome due to viridans streptococci: A case-control study of predisposing factors. Clin Infect Dis 14:1201-1207, 1992
17. Paganini H, Staffolani V, Zubizarreta P, et al: Viridans streptococci bacteraemia in children with fever and neutropenia: A case-control study of predisposing factors. Eur J Cancer 39:1284-1289, 2003
18. Steiner M, Villablanca J, Kersey J. et al: Viridans streptococcal shock in bone marrow transplantation patients. Am J Hematol 42:354-358, 1993
19. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibiltiy Testing (ed 6). Villanova, PA, National Committee for Clinical Laboratory Standards, 1995
20. Marron A, Carratala J, Gonzalez-Barca E, et al: Serious complications of bacteremia caused by Viridans streptococci in neutropenic patients with cancer. Clin Infect Dis 31:1126-1130, 2000
21. Soto A, McWhinney PH, Kibbler CC, et al: Cytokine release and mitogenic activity in the viridans streptococcal shock syndrome. Cytokine 10:370-376, 1998
22. Lu HZ, Weng XH, Zhu B, et al: Major outbreak of toxic shock-like syndrome caused by Streptococcus mitis. J Clin Microbiol 41:3051-3055, 2003
23. Klaassen RJ, Goodman TR, Pham B. et al: "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 18:1012-1019, 2000
24. Klastersky J, Paesmans M, Rubenstein EB, et al: The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038-3051, 2000
25. Talcott JA, Finberg R, Mayer RJ, et al: The medical course of cancer patients with fever and neutropenia: Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148:2561-2568, 1988
26. Talcott JA, Siegel RD, Finberg R, et al: Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316-322, 1992
27. Alexander SW, Wade KC, Hibberd PL, et al: Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 24:38-42, 2002
28. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 163:951-958, 1991
29. Elting LS, Rubenstein EB, Rolston KV, et al: Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25:247-259, 1997
30. Alejandria MM, Lansang MA, Dans LF, et al: Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev CD001090, 2002
31. Darenberg J, Ihendyane N, Sjolin J, et al: Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 37:333-340, 2003
32. Kaul R, McGeer A, Norrby-Teglund A, et al: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: A comparative observational study-The Canadian Streptococcal Study Group. Clin Infect Dis 28:800-807, 1999